Table 1:
Descriptive statistics [mean (SD)] of study sample
| Testosterone | Placebo | All | |
|---|---|---|---|
| Sample size | 58 | 57 | 115 |
| Testosterone (pg/mL) | |||
| Baseline | 136.3 (172.3) | 112.5 (188.1) | 124.5 (179.9) |
| Pre-Competition1 | 2768.5 (2130.7) | 108.1 (95.3) | 1449.9 (2014.8) |
| Post-Competition1 | 3229.0 (2167.1) | 244.7 (426.6) | 1750.0 (2164.2) |
| Cortisol (μg/dL) | |||
| Baseline | 0.367 (0.209) | 0.310 (0.181) | 0.339 (0.197) |
| Pre-Competition | 0.213 (0.154) | 0.217 (0.127) | 0.215 (0.141) |
| Post-Competition | 0.154 (0.089) | 0.163 (0.090) | 0.158 (0.090) |
| Decisions to Compete (% of choice trials in Initial Phase) | 67.5 (25.6) | 59.1 (30.1) | 63.3 (28.1) |
| Male Opponents | 60.3 (29.5) | 54.4 (33.9) | 57.4 (31.8) |
| Female Opponents | 74.6 (26.4) | 63.8 (31.7) | 69.2 (29.5) |
| Decisions to Compete Again (% of choices in Feedback Phase) | 48.6 (23.9) | 47.7 (23.5) | 48.2 (23.6) |
| Male Opponents2 | 49.1 (28.1) | 43.9 (27.8) | 46.6 (28.0) |
| Female Opponents2 | 54.1 (28.8) | 57.5 (25.8) | 55.8 (27.3) |
| Prior Winners3 | 47.0 (37.1) | 42.4 (33.6) | 44.7 (35.3) |
| Prior Losers3 | 60.9 (40.8) | 64.1 (38.6) | 62.4 (39.6) |
| Trial Score (all trials in Initial Phase) | 2.59 (0.99) | 2.52 (0.73) | 2.55 (0.87) |
Notes:
1.
A portion of samples in the testosterone treatment group were above the maximum values of the kits used. For the purposes of calculating these means, the missing values were replaced with the kit’s maximum levels.
2.
Regardless of prior win/loss.
3.
Regardless of opponent gender. “Winners” and “losers” in these rows refers to the opponent – e.g., “prior winners” are opponents that won a mandatory compete trial against the participant in the initial phase.